Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer With Low Expression of HER2”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Large-scale testing (Phase 3)Looking for participantsNCT04400695
What this trial is testing

RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 366
Not applicableLooking for participantsNCT07331506
What this trial is testing

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

Who this might be right for
Breast Cancer DetectionBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer Female+5 more
Oncoliq US Inc 300
Testing effectiveness (Phase 2)Ended earlyNCT02115048
What this trial is testing

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Who this might be right for
Breast Neoplasms
Translational Research in Oncology 44
Post-approval studies (Phase 4)UnknownNCT05861635
What this trial is testing

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Who this might be right for
Breast CancerNeoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 42
Not applicableUnknownNCT05834699
What this trial is testing

HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Who this might be right for
Breast Cancer
Beijing 302 Hospital 50
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Testing effectiveness (Phase 2)UnknownNCT05749575
What this trial is testing

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Who this might be right for
Breast Cancer
Sun Yat-sen University 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625
What this trial is testing

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Who this might be right for
Untreated Early-stage or Locally Advanced Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)UnknownNCT05018676
What this trial is testing

ARX788 in Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer With Low Expression of HER2
Fudan University 54
Early research (Phase 1)Looking for participantsNCT05872295
What this trial is testing

IKS014 in Advanced Solid Tumors That Express HER2

Who this might be right for
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd. 165
Testing effectiveness (Phase 2)Study completedNCT03052634
What this trial is testing

RC48-ADC in Subjects With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RemeGen Co., Ltd. 112
Not applicableNot Yet RecruitingNCT07689929
What this trial is testing

Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 900
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189884
What this trial is testing

Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy

Who this might be right for
Locally Advanced Breast Cancer (LABC)
The First Affiliated Hospital of Xiamen University 33
Not applicableNot Yet RecruitingNCT07670182
What this trial is testing

The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer

Who this might be right for
Patients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05546268
What this trial is testing

Study of Oral MRT-2359 in Selected Cancer Patients

Who this might be right for
NSCLCSCLCHigh Grade Neuroendocrine Cancer+5 more
Monte Rosa Therapeutics, Inc 174
Not applicableLooking for participantsNCT07630402
What this trial is testing

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Who this might be right for
Breast Cancer With Low to Intermediate HER2 Expression
University of Rochester 20
Testing effectiveness (Phase 2)Looking for participantsNCT05911958
What this trial is testing

SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Who this might be right for
HER2 Low Breast Carcinoma
Henan Cancer Hospital 66
Testing effectiveness (Phase 2)Ended earlyNCT00351858
What this trial is testing

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsBreast Cancer
Neovii Biotech 40
Testing effectiveness (Phase 2)Looking for participantsNCT07817082
What this trial is testing

Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer With Ultra-Low HER2 Expression
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Next Page